Sotrovimab Expanded Access Treatment Protocol (COVID-19)
Purpose
An expanded access program for sotrovimab administered intravenously to participants with COVID-19 illness who meet current authorized/approved criteria for use of sotrovimab.
Condition
- Covid19
Eligibility
- Eligible Ages
- Over 12 Years
- Eligible Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- In the opinion of the investigator, meets the current Emergency Use Authorization (EUA) eligibility criteria for sotrovimab OR - patients currently hospitalized for a non-COVID-19 illness who acquire COVID-19 (nosocomial infection) and otherwise meets all the current EUA eligibility criteria
Exclusion Criteria
- Hospitalized due to COVID-19 (excludes nosocomial infection) - Require oxygen therapy due to COVID-19, OR who require an increase in baseline oxygen flow rate due to COVID-19
Study Design
- Phase
- Study Type
- Expanded Access
Recruiting Locations
Site
Palo Alto, California 94304
Palo Alto, California 94304
Site
Boston, Massachusetts 02114
Boston, Massachusetts 02114
Site
St Louis, Missouri 63110
St Louis, Missouri 63110
Site
Seattle, Washington 98109
Seattle, Washington 98109
More Details
- NCT ID
- NCT05235347
- Status
- No longer available
- Sponsor
- Vir Biotechnology, Inc.